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Abstract
Genome-wide association studies using genotype data have had limited success in the identiﬁcation of variants
associated with major depressive disorder (MDD). Haplotype data provide an alternative method for detecting
associations between variants in weak linkage disequilibrium with genotyped variants and a given trait of interest. A
genome-wide haplotype association study for MDD was undertaken utilising a family-based population cohort,
Generation Scotland: Scottish Family Health Study (n = 18,773), as a discovery cohort with UK Biobank used as a
population-based replication cohort (n = 25,035). Fine mapping of haplotype boundaries was used to account for
overlapping haplotypes potentially tagging the same causal variant. Within the discovery cohort, two haplotypes
exceeded genome-wide signiﬁcance (P < 5 × 10−8) for an association with MDD. One of these haplotypes was
nominally signiﬁcant in the replication cohort (P < 0.05) and was located in 6q21, a region which has been previously
associated with bipolar disorder, a psychiatric disorder that is phenotypically and genetically correlated with MDD.
Several haplotypes with P < 10−7 in the discovery cohort were located within gene coding regions associated with
diseases that are comorbid with MDD. Using such haplotypes to highlight regions for sequencing may lead to the
identiﬁcation of the underlying causal variants.
Introduction
Major depressive disorder (MDD) is a complex and
clinically heterogeneous condition with core symptoms of
low mood and/or anhedonia over a period of at least two
weeks. MDD is frequently comorbid with other clinical
conditions, such as cardiovascular disease1, cancer2 and
inﬂammatory diseases3. This complexity and comorbidity
suggests heterogeneity of aetiology and may explain why
there has been limited success in identifying causal
genetic variants4–7, despite heritability estimates ranging
from 28 to 37%8,9. Single-nucleotide polymorphism
(SNP)-based analyses are unlikely to fully capture the
variation in regions surrounding the genotyped markers,
including untyped lower-frequency variants and those
that are in weak linkage disequilibrium (LD) with the
common SNPs on many genotyping arrays.
Haplotype-based analysis may help improve the detec-
tion of causal genetic variants as, unlike single SNP-based
analysis, it is possible to assign the strand of sequence
variants and combine information from multiple SNPs to
identify rarer causal variants. A number of studies10–12
have identiﬁed haplotypes associated with MDD, albeit by
focussing on particular regions of interest. In the current
study, a family and population-based cohort Generation
Scotland: Scottish Family Health Study (GS:SFHS) was
utilised to ascertain genome-wide haplotypes in closely
and distantly related individuals13. A haplotype-based
association analysis was conducted using MDD as a
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phenotype, followed by additional ﬁne mapping of hap-
lotype boundaries with a replication and meta-analysis
performed using the UK Biobank cohort14.
Materials and methods
Discovery cohort
The discovery phase of the study used the family and
population-based Generation Scotland: Scottish Family
Health Study (GS:SFHS) cohort13, consisting of 23,960
individuals of whom 20,195 were genotyped with the
Illumina OmniExpress BeadChip (706,786 SNPs). Indivi-
duals with a genotype call rate <98% were removed, as
well as those SNPs with a call rate <98%, a minor allele
frequency (MAF)< 0.01 or those deviating from
Hardy–Weinberg equilibrium (P< 10−6). Individuals who
were identiﬁed as population outliers through principal
component analyses of their genotypic information were
also removed15.
Following quality control there were 19,904 GS:SFHS
individuals (11,731 females and 8173 males) that had
genotypic information for 561,125 autosomal SNPs.
These individuals ranged from 18–99 years of age with an
average age of 47.4 years and a standard deviation of 15.0
years. There were 4933 families that had at least two
related individuals, this included 1799 families with two
members, 1216 families with three members and 829
families with four members. The largest family group
consisted of 31 related individuals and there were 1789
individuals that had no other family members within GS:
SFHS.
Replication cohort
The population-based UK Biobank16 (provided as part
of project #4844) was used as a replication cohort to
assess those haplotypes within GS:SFHS with P< 10−6.
The UK Biobank data consisted of 152,249 individuals
with genomic data for 72,355,667 imputed variants17. The
SNPs genotyped in GS:SFHS were extracted from the UK
Biobank data and those variants with an imputation
accuracy <0.8 were removed, leaving 555,782 variants in
common between the two cohorts. Those genotyped
individuals listed as non-white British and those that had
also participated in GS:SFHS were removed from within
UK Biobank, leaving a total of 119,955 individuals.
Genotype phasing and haplotype formation
The genotype data for GS:SFHS and UK Biobank was
phased using SHAPEIT v2.r83718. Genome-wide phasing
was conducted on the GS:SFHS cohort, while the phasing
of UK Biobank was conducted on a 50Mb window
centred on those haplotypes identiﬁed within GS:SFHS
with P< 10−6. The relatedness within GS:SFHS made it
suitable for the application of the duoHMM method,
which improves phasing accuracy by also incorporating
family information19. The default window size of 2Mb
was used for UK Biobank and a 5Mb window was used
for GS:SFHS as larger window sizes have been demon-
strated to be beneﬁcial when there is increased identity by
descent (IBD) in the population18. The number of con-
ditioning states per SNP was increased from the default of
100 states to 200 states to improve phasing accuracy, with
the default effective population size of 15,000 used. To
calculate the recombination rates between SNPs during
phasing the HapMap phase II b3720 was used. This build
was also used to partition the phased data into haplotypes.
Three window sizes (1cM, 0.5cM and 0.25cM) were
used to establish the SNPs that formed each haplotype21.
Each window was then moved along the genome by a
quarter of the respective window size. There were a total
of 97,333 windows with a mean number of SNPs per
window of 157, 79 and 34 for the 1, 0.5 and 0.25cM
windows, respectively. Windows that were less ﬁve SNPs
in length were removed. The frequency (p) of each
observed haplotype (A) was calculated as:
p ¼ 2X obs AAð Þ þ obs Aað Þ
2X obs AAð Þ þ obs Aað Þ þ obs aað Þð Þ
where a represents all other haplotypes in that window. A
chi-squared test for Hardy–Weinberg equilibrium (X2) for
each haplotype was calculated as:
X2 ¼ obs AAð Þ  p
2n
p2n
þ obs Aað Þ  2 pqn
2 pqn
þ obs aað Þ  q
2n
q2n
where n is the number of individuals and q= 1− p.
Haplotypes with 0.995< p< 0.005 or with X2> 24 (P<
10−6) were not tested for association, however, they were
included within the alternative haplotype. Following this
quality control there were a total of 2,618,094 haplotypes
remaining for analysis. The reported haplotype positions
relate to the outermost SNPs within each haplotype are in
base pair (bp) position according to GRCh37.
To approximate the number of independently segre-
gating haplotypes the clump command within Plink
v1.9022 was applied. This provides an estimation of the
Bonferroni correction required for multiple testing. When
applying an LD r2 threshold of <0.4 there were 1,070,216
independently segregating haplotypes within GS:SFHS,
equating to a P-value< 5× 10−8 for genome-wide sig-
niﬁcance. This threshold is also frequently applied to
SNP-based and sequence-based association studies to
account for multiple testing23.
Phenotype ascertainment
Discovery cohort
Within GS:SFHS a diagnosis of MDD was made using
initial screening questions and the Structured Clinical
Interview for the Diagnostic and Statistical Manual of
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Mental Disorders (SCID)24. The SCID is an inter-
nationally validated approach to identifying episodes of
depression and was conducted by clinical nurses trained
in its administration. Further details regarding this diag-
nostic assessment have been described previously25. In
this study, MDD was deﬁned by at least one instance of a
major depressive episode which initially identiﬁed 2659
cases, 17,237 controls and 98 missing (phenotype
unknown) individuals.
In addition, the psychiatric history of cases and controls
was examined using the Scottish Morbidity Record26.
Within the control group, 1072 participants were found
to have attended at least one psychiatry outpatient
clinic and were excluded from the study. In addition,
47 of the MDD cases were found to have additional
diagnoses of either bipolar disorder or schizophrenia
in psychiatric inpatient records and were also excluded
from the study. These participants had given prior con-
sent for anonymised access to routine administrative
clinical data.
In total there were 2605 MDD cases and 16,168 controls
following the removal of individuals based on patient
records and population stratiﬁcation, equating to a pre-
valence of 13.9% for MDD in this cohort.
Replication cohort
Within the UK Biobank cohort, 25,035 participants
(12,528 males and 12,507 females) completed a touchsc-
reen assessment of depressive symptoms and previous
treatment. These participants ranged from 40 to 79 years
of age with a mean age of 57.8 years and a standard
deviation of 8.0 years. On the basis of their responses to
items from the Patient Health Questionnaire, diagnostic
status was deﬁned as either ‘probable single lifetime epi-
sode of major depression’ or ‘probable recurrent major
depression (moderate and severe)’ and with control status
deﬁned as ‘no mood disorder’ using the deﬁnitions pro-
vided by Smith et al.14. MDD Cases were deﬁned by
reporting that they had ever been depressed/down for a
whole week (UK Biobank ﬁeld number 4598); plus this
was for at least a two week period (UK Biobank ﬁeld
number 4609); plus this was for at least one episode (UK
Biobank ﬁeld number 4620); plus ever seen a GP (UK
Biobank ﬁeld number 2090) or psychiatrist (UK Biobank
ﬁeld number 2100) for nerves, anxiety, tension or
depression. Alternatively, MDD cases were also deﬁned by
reporting that they had ever been uninterested in things
or unable to enjoy the things you used to for at least a
whole week (UK Biobank ﬁeld number 4631); plus this
was for at least a two week period (UK Biobank ﬁeld
number 5375); plus this was for at least one episode (UK
Biobank ﬁeld number 5386); plus ever seen a GP (UK
Biobank ﬁeld number 2090) or psychiatrist (UK Biobank
ﬁeld number 2100) for nerves, anxiety, tension or
depression. In total there were 8508 cases and 16,527
controls, equating to a trait prevalence of 34.0% in this
cohort, after the removal of individuals with insufﬁcient
information or ambiguous phenotypes.
Statistical approach
Discovery cohort
A mixed linear model was used to conduct an associa-
tion analysis using GCTA v1.25.0:27
y ¼ Xβþ Z1uþ Z2vþ ε
where y was the vector of binary observations for MDD.
β was the matrix of ﬁxed effects, including haplotype, sex,
age and age2. Each unique haplotype was represented as a
distinct allele and was either coded as 0, 1 or 2 depending
on the number of haplotypes carried by that individual. u
was ﬁtted as a random effect taking into account the
genomic relationships (MVN (0,Gσ2u), where G was a
SNP-based genomic relationship matrix28). v was a ran-
dom effect ﬁtting a second genomic relationship matrix
Gt(MVN (0,Gtσ2v) which modelled only the more closely
related individuals29. Gt was equal to G except that off-
diagonal elements <0.05 were set to 0. X, Z1 and Z2 were
the corresponding incidence matrices. ε was the vector of
residual effects and was assumed to be normally dis-
tributed, MVN (0,Iσ2ε).
The inclusion of the second genomic relationship
matrix, Gt, was deemed desirable as the ﬁtting of the
single matrix G alone resulted in signiﬁcant population
stratiﬁcation (intercept= 1.029± 0.003, λGC= 1.026)
following examination with LD score regression30. The
ﬁtting of both genomic relationship matrices simulta-
neously produced no evidence of bias due to population
stratiﬁcation (intercept= 1.002 ± 0.003, λGC= 1.005).
Replication cohort
A mixed linear model was used to assess the haplotypes
in UK Biobank, which were identiﬁed in the discovery
cohort with P< 10−6 using GCTA v1.25.0:27
y ¼ Xβþ Z1uþ ε
where y was the vector of binary observations for MDD.
β was the matrix of ﬁxed effects, including haplotype, sex,
age, age2, genotyping batch and recruitment centre. u was
ﬁtted as a random effect taking into account the SNP-
based genomic relationships (MVN (0,Gσ2u).X and Z1
were the corresponding incidence matrices and ε was the
vector of residual effects and was assumed to be normally
distributed, MVN (0, Iσ2ε ). Replication success was judged
on the statistical signiﬁcance of each haplotype using an
inverse variance-weighted meta-analysis across both
cohorts conducted using Metal31.
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Fine mapping
The method described above examines the effect of
each haplotype against all other haplotypes in that win-
dow. Therefore, a haplotype could be assessed against
similar haplotypes containing the same causal variant,
limiting any observed phenotypic association. To inves-
tigate whether there were causal variants located within
directly overlapping haplotypes of the same window size,
ﬁne mapping of haplotype boundaries was used. Where
there were directly overlapping haplotypes, each with P<
10−3 and with an effect in the same direction, i.e., both
causal or both preventative, then any shared consecutive
regions formed a new haplotype that was assessed using
the mixed-model described previously. This new haplo-
type was assessed using all individuals and was required to
be at least ﬁve SNPs in length. A total of 47 new haplo-
types were assessed from within 26 pairs of directly
overlapping haplotypes.
Results
An association analysis for MDD was conducted using
2,618,094 haplotypes and 47 ﬁne mapped haplotypes
within the discovery cohort, GS:SFHS. A genome-wide
Manhattan plot of –log10 P-values for these haplotypes is
provided in Fig. 1 with a q–q plot provided in Supple-
mentary Fig. S1. Within the discovery cohort, two
haplotypes exceeded genome-wide signiﬁcance (P< 5×
10−8) for an association with MDD, one located on
chromosome 6 and the other located on chromosome 10.
There were 12 haplotypes with P< 10−6 in the discovery
cohort with replication sought for these haplotypes using
UK Biobank. Summary statistics from both cohorts and
the meta-analysis for these 12 haplotypes are provided in
Table 1. The protein coding genes which overlap these 12
haplotypes along with the observed haplotype frequencies
within the two cohorts are provided in Table 2. The SNPs
and alleles that constitute these 12 haplotypes are pro-
vided in Supplementary Table S1.
The two haplotypes on chromosome 6 (LD r2= 0.74)
with P< 10−6 in the discovery cohort both achieved
nominal signiﬁcance (P< 0.05) in the replication cohort
(although these would not survive multiple testing cor-
rection for the 12 SNPs tested in the replication data set),
with one reaching genome-wide signiﬁcance (P< 5×
10−8) in the meta-analysis. A regional association plot of
the region surrounding these haplotypes within GS:SFHS
is provided in Fig. 2. Fine mapping was used to form the
most signiﬁcant haplotype within the discovery cohort.
Two directly overlapping 0.5 cM haplotypes consisting of
28 SNPs were identiﬁed between 108,335,345 and
108,454,437 bp (rs7749081–rs212829). These two haplo-
types had P-values of 3.24× 10−5 and 5.57× 10−5,
Fig. 1 Manhattan plot representing the –log10 P-values for an association between each assessed haplotype in the Generation Scotland: Scottish
Family Health Study cohort and Major Depressive Disorder
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respectively, and differed at a single SNP (rs7749081).
Exclusion of this single SNP deﬁned a new 27 SNP hap-
lotype that had a genome-wide signiﬁcant association
with MDD (P= 7.06× 10−9). Calculating the effect size at
the population level32, the estimates of the contribution of
the two haplotypes to the total genetic variance was
2.09× 10−4 and 2.38× 10−4, respectively, within GS:
SFHS. None of the individual SNPs located within either
haplotype were associated with MDD in either cohort
(P ≥ 0.05).
A genome-wide signiﬁcant haplotype (P= 8.50× 10−9)
was identiﬁed on chromosome 10 within GS:SFHS using a
0.5 cM window. A regional association plot of the region
surrounding this haplotype is provided in Fig. 3. This
haplotype had an odds ratio (OR) of 2.33 (95% conﬁdence
interval (CI): 1.83 – 2.91) in the discovery cohort and an
OR of 1.15 (95% CI: 0.80–1.59) in the replication cohort.
These were the highest ORs observed in the respective
cohorts. The estimate of the contribution of this haplo-
type to the total genetic variance was 2.29× 10−4 in the
discovery cohort. Association analysis of the 92 SNPs on
this haplotype revealed that one SNP in GS:SFHS
(rs17133585) and two SNPs in UK Biobank (rs12413638
and rs10904290) were nominally signiﬁcant (P< 0.05),
although none had P-values < 0.001.
All 12 of the haplotypes with a P-value for association
<10−6 in the GS:SFHS discovery cohort were risk factors
for MDD (OR> 1). Within the replication cohort, 7 out of
these 12 haplotypes had OR> 1, however, only of two of
these had the lower bound of the 95% conﬁdence interval
> 1. None of the 95% conﬁdence intervals for the repli-
cation ORs overlapped the 95% conﬁdence intervals of the
discovery GS:SFHS cohort.
Discussion
Twelve haplotypes were identiﬁed in the discovery
cohort with P< 10−6 of which two were signiﬁcant at
the genome-wide level (P< 5× 10−8) in the discovery
cohort and one which was genome-wide signiﬁcant
(P< 5× 10−8) in the meta-analysis. A power analysis33
was conducted using the genotype relative risks observed
in the discovery cohort, the sample sizes and haplo-
type frequencies in the replication cohort and the pre-
valence of MDD reported for a structured clinical diag-
nosis of MDD in other high income counties (14.6%)34.
There was sufﬁcient power (>0.99) to detect the twelve
haplotypes with P< 10−6 identiﬁed in the discovery
cohort within the replication cohort at a signiﬁcance
threshold of 0.05.
There are several reasons why the effect sizes observed
in the replication cohort were lower than those observed
in the discovery cohort. The causal loci may have been in
lower LD with the assessed haplotypes in the replication
cohort than in the discovery cohort lessening theTa
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observed effect. The phenotypes across the two cohorts
were potentially heterogeneous (certainly with regards to
the prevalence in each population) so the assessed hap-
lotypes may have had differing effects on each cohort’s
phenotype. A complementary approach to replication is
to identify the gene coding regions within haplotypes that
potentially provide a biologically informative explanation
for an association with MDD. Those haplotypes with
Fig. 2 Regional association plot representing the –log10 P-values for an association between haplotypes in the Generation Scotland: Scottish Family
Health Study cohort and Major Depressive Disorder within the 107.4–107.6 Mb region on chromosome 6. The start and end position (using build
GRCh37) of haplotypes represent the outermost SNP positions within the windows examined. The warmth of colour represents the r2 with the
genome-wide signiﬁcant haplotype located between 108,338,267 and 108,454,437 bp
Table 2 Protein coding genes located overlapping with the 12 haplotypes with P < 10−6 in the generation Scotland:
Scottish family health study (GS:SFHS) discovery cohort and the frequencies of those haplotypes in GS:SFHS and UK
Biobank
Haplotype frequency
Chr. Position (bp) Protein coding genes GS:SFHS UK Biobank
6 108,338,267–108,454,437 OSTM1 0.0152 0.0197
6 108,407,662–108,454,437 OSTM1 0.0193 0.0241
7 139,682,412–139,708,901 TBXAS1 0.0066 0.0069
8 79,700,362–80,387,861 IL7 0.0076 0.0081
8 79,759,499–80,156,474 IL7 0.0147 0.0157
10 4,588,261–4,822,210 0.0064 0.0027
11 2,260,854–2,437,425 ASCL2, CLorf21, TSPAN32, CD81, TSSC4, TRPM5 0.0196 0.0187
12 48,159,721–48,263,828 SLC48A1, RAPGEF3, HDAC7, VDR 0.0078 0.0090
12 116,904,503–117,062,860 MAP1LC3B2 0.0057 0.0045
15 49,206,902–49,260,601 SHC4 0.0082 0.0080
15 93,806,447–93,851,224 0.0224 0.0206
15 93,821,340–93,845,622 0.0265 0.0243
Base pair (bp) positions are based on build GRCh37 with protein coding regions obtained from Ensembl, GRCh37.p13. Haplotype frequencies were calculated using
unrelated individuals and excluding UK Biobank participants recruited in Glasgow or Edinburgh. { indicates a linkage disequilibrium (r2) > 0.5 between haplotypes in
the GS:SFHS cohort
{
{
{
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P< 10−7 in the discovery cohort and the gene coding
regions that they overlap are discussed below.
The two haplotypes on chromosome 6 overlapped with
the Osteopetrosis Associated Transmembrane Protein 1
(OSTM1) coding gene. OSTM1 is associated with neuro-
degeneration35,36 and melanocyte function37, and alpha-
melanocyte-stimulating hormone has been shown to have
an effect on depression-like symptoms38–40. This haplo-
type lies within the 6q21 region that has been associated
with bipolar disorder41–45, a disease that shares symptoms
with MDD and has a correlated phenotypic liability of
0.6446. This may indicate either a pleiotropic effect or
clinical heterogeneity, whereby patients may be mis-
diagnosed, i.e., patients may have MDD and transition to
bipolar disorder in the future or are sub-threshold for
bipolar disorder and instead given a diagnosis of MDD.
The haplotype identiﬁed on chromosome 8 overlapped
with the Interleukin 7 (IL7) protein coding region. IL7 is
involved in maintaining T-cell homoeostasis47 and pro-
liferation48, which in turn contributes to the immune
response to pathogens. It has been proposed that
impaired T-cell function may be a factor in the develop-
ment of MDD49, with depressed subjects found to have
elevated50 or depressed levels51 of IL7 serum. There is
conjecture as to whether MDD causes inﬂammation or
represents a reaction to an increased inﬂammatory
response52,53, but it is most likely to be a bidirectional
relationship51.
The haplotype on chromosome 10 overlapped with two
RNA genes: long intergenic non-protein coding RNA 704
(LINC00704) and long intergenic non-protein coding
RNA 705 (LINC00705). The function of these non-protein
coding genes is unreported. However, a study of cardiac
neonatal lupus, which is a rare autoimmune disease
demonstrated an association for a SNP (rs1391511) which
is 15kb from LINC00705.
Two Dutch studies54,55 have identiﬁed a variant
(rs8023445) on chromosome 15 located within the SRC
(Src homology 2 domain containing) family, member 4
(SHC4) gene coding region that has a moderate degree of
association with MDD (P= 1.64× 10−5 and P= 9× 10−6,
respectively). A variant (rs10519201) within the SHC4
coding region was also found to have an association (P=
6.16× 10−6) with Obsessive-Compulsive Personality
Disorder in a UK-based study56. SHC4 is expressed in
neurons57 and regulates BDNF-induced MAPK activa-
tion58, which has been shown to be a key factor in MDD
pathophysiology59. The SHC4 region overlaps with the
haplotype on chromosome 15 identiﬁed in the discovery
cohort (located at 49,206,902–49,260,601 bp) and, there-
fore, further research to examine the association between
the SHC4 region and psychiatric disorders could be
warranted.
Haplotype-based analyses are capable of tagging var-
iants due to the LD between the untyped variants and the
multiple ﬂanking genotyped variants which make up the
inherited haplotype. This approach should provide greater
power when there is comparatively higher IBD sharing,
such as in GS:SFHS which was a family-based cohort,
where there is a greater likelihood that a single haplotype
Fig. 3 Regional association plot representing the –log10 P-values for an association between haplotypes in the Generation Scotland: Scottish Family
Health Study cohort and Major Depressive Disorder within the 3.6–5.8 Mb region on chromosome 10. The start and end position (using build
GRCh37) of haplotypes represent the outermost SNP positions within the windows examined. The warmth of colour represents the r2 with the
genome-wide signiﬁcant haplotype located between 4,588,261 and 4,822,210 bp
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is tagging the same causal variant across that population.
The UK Biobank was selected as replication cohort as it is
a large population-based sample that was expected to be
genetically similar to the GS:SFHS discovery cohort. This
was conﬁrmed by the similarity of the observed haplotype
frequencies (Table 2) between the two cohorts. The pre-
valence of MDD observed in the discovery cohort (13.7%)
was comparable to that reported (14.6%) within similar
populations34. However, in the replication cohort, the
trait prevalence was notably higher (34.0%), most likely
due to the differing methods of phenotypic ascertainment.
Additional work could seek to replicate the ﬁndings in
further cohorts, as well as full meta-analysis of all hap-
lotypes within those cohorts. An additive model was used
to analyse the haplotypes and alternative approaches
could implement a dominant model or an analysis of
diplotypes (haplotype pairs) for association with MDD.
Conclusions
This study identiﬁed two haplotypes within the dis-
covery cohort that exceeded genome-wide signiﬁcance for
association with a clinically diagnosed MDD phenotype.
One of these haplotypes was nominally signiﬁcant in the
replication cohort and was in LD with a haplotype that
was genome-wide signiﬁcant in the meta-analysis. The
genome-wide signiﬁcant haplotype on chromosome 6 was
located on 6q21, which has been shown previously to be
related to psychiatric disorders. There were a number of
haplotypes approaching genome-wide signiﬁcance located
within genic regions associated with diseases that are
comorbid with MDD and, therefore, these regions war-
rant further investigation. The total genetic variance
explained by the haplotypes identiﬁed was small, however,
these haplotypes potentially represent biologically infor-
mative aetiological subtypes for MDD and merit further
analysis.
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